Search Results

ContraFect Corporation announces business updates and financial results for the second quarter ended June 30, 2023.

ContraFect Corporation today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston.

ContraFect Corporation today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023.

ContraFect Corporation announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.

ContraFect Corporation announces that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company’s common stock.

ContraFect Corporation (Nasdaq: CFRX) today announces business updates and financial results for the first quarter ended March 31, 2023.

ContraFect Corporation(Nasdaq: CFRX) today announces business updates and financial results for the fourth quarter and full year ended December 31, 2022.

ContraFect Corporation announced financial results and business updates for the third quarter ended September 30, 2022.

ContraFect Corporation announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.

ContraFect Corporation (Nasdaq: CFRX) today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), and concluded that the company may proceed with its Phase 1 clinical study.